CHA₂DS₂-VASc Score Calculator

About the CHA₂DS₂-VASc Score Calculator

The CHA₂DS₂-VASc Score Calculator estimates annual stroke risk in patients with non-valvular atrial fibrillation and helps organize anticoagulation decisions. It builds on CHADS₂ by adding vascular disease, age 65-74, and female sex to improve risk separation at the lower end of the scale.

Scores range from 0 to 9. Higher scores point to higher stroke risk and usually support a stronger case for anticoagulation, depending on the full clinical picture.

When This Page Helps

Use the CHA₂DS₂-VASc score to separate lower-risk atrial fibrillation patients from those who may benefit more clearly from stroke prevention. It helps balance stroke prevention against the risk of bleeding.

The score is also useful when comparing patients with similar CHADS₂ results, since it adds a few extra risk factors that can change the decision.

How to Use the Inputs

1. Confirm the patient has non-valvular atrial fibrillation.
2. Assess for congestive heart failure or LV dysfunction.
3. Record hypertension history.
4. Note the patient age category.
5. Check for diabetes mellitus.
6. Review history for prior stroke, TIA, or thromboembolism.
7. Assess for vascular disease (MI, PAD, aortic plaque).

Example Calculation

Tips & Best Practices

• Age ≥75 receives 2 points, not 1 — this is the most heavily weighted factor after stroke history.
• Prior stroke/TIA/thromboembolism also receives 2 points — secondary prevention is critical.
• Female sex is only a risk modifier — do not anticoagulate based on female sex alone.
• Always calculate HAS-BLED alongside CHA₂DS₂-VASc for balanced decision-making.
• DOACs are preferred over warfarin in most patients — fewer interactions, no INR monitoring.
• Renal function affects DOAC choice and dosing — always check CrCl.

Guideline Recommendations

ESC guidance recommends: Score 0 (males) or 1 (females, sex factor only) — no antithrombotic therapy. Score 1 (males) — OAC should be considered. Score ≥2 — OAC is recommended. The AHA/ACC guidance is similar, with slightly different phrasing about the score 1 category.

DOACs vs Warfarin

Four DOACs are approved for AF stroke prevention: apixaban (ARISTOTLE), rivaroxaban (ROCKET AF), edoxaban (ENGAGE AF), and dabigatran (RE-LY). Meta-analyses show DOACs reduce stroke/systemic embolism by 19% and intracranial hemorrhage by 52% compared to warfarin. Apixaban showed the best safety profile in trials.

Emerging Concepts

Ongoing research examines whether patients with very low CHA₂DS₂-VASc scores detected by wearable ECG monitoring benefit from anticoagulation. The relationship between AF burden (time in AF vs total monitoring time) and stroke risk is under active investigation, potentially refining treatment decisions beyond simple yes/no anticoagulation.

Frequently Asked Questions

• Do female patients with a score of 1 (sex factor only) need anticoagulation?

  No. Female sex alone (score 1 in an otherwise zero patient) is considered "low risk" per guidelines. The sex factor is only relevant when other risk factors are present. ESC guidelines recommend viewing female sex as a "risk modifier" rather than an independent risk factor.

• Which anticoagulant is preferred for AF?

  DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) are preferred over warfarin for most patients with non-valvular AF based on superior efficacy, safety profile, and convenience. Warfarin remains first-line for mechanical heart valves and moderate-to-severe mitral stenosis.

• Should the score be recalculated over time?

  Yes. Risk factors accumulate with age and comorbidities. A patient who is low-risk at age 50 may become high-risk by age 65-75. Annual reassessment is recommended, especially around age thresholds.

• Does the CHA₂DS₂-VASc score apply to paroxysmal AF?

  Yes. Stroke risk and anticoagulation recommendations are the same regardless of AF pattern (paroxysmal, persistent, or permanent). All AF types carry similar long-term stroke risk.

• What is the role of HAS-BLED with CHA₂DS₂-VASc?

  HAS-BLED estimates bleeding risk on anticoagulation. Both scores should be calculated together. A high HAS-BLED score does not necessarily contraindicate anticoagulation but identifies modifiable bleeding risk factors and indicates closer monitoring.

• What about left atrial appendage closure?

  LAA closure devices (Watchman) are an alternative for patients with high stroke risk who cannot tolerate long-term anticoagulation. They are not first-line therapy and require careful patient selection.